Introduction: Partial lipodystrophy (PL) is a rare disease associated with insulin resistance and metabolic dysfunctions, including NAFLD. Global prevalence of NAFLD is ±25%. In PL patients NAFDL prevalence and severity remains unclear. AIMS To evaluate the presence of hepatic steatosis and/or fibrosis in PL patients using transient elastography (TE) in comparison to a control group.

Materials and Methods: Fifteen patients (7 with PL of the limbs, 8 with Familiar Partial Lipodystrophy Dunnigan-type) and 15 (13 women) controls paired to BMI and age were included. We recruited participants aged 18-65 years-old and a BMI≥25 and ≤35kg/m², excluding other causes of steatohepatitis. Anthropometric measures, metabolic parameters and the presence of steatosis/fibrosis using TE(Fibroscan®) were evaluated. According to literature, the adopted cut-off values in TE for Controlled Attenuation Parameter (CAP) and Liver Stiffness Measurement (LSM) are ≥238dB/m and ≥5,8kPa, respectively. Student t-test was used for continuous variables. Main results are presented as Mean ± SD.

Results: Mean age was 52.93 and 50.26 years-old in PL and control groups, respectively. BMI was slightly but not significantly higher in control group (30,13kg/m² [SD±2,85] vs. 27,43kg/m² [SD±5,30]). Waist-to-hip ratio did not differ. PL group had higher fasting plasma glucose (116.78mg/dL [SD±39,54] vs. 89,58mg/dL [SD±23,34], p= 0,0476). No differences in hepatic lesion biomarkers or lipid profile was noted, except for a lower HDL-c in PL group (40,64mg/dL [SD±9,45] vs. 49,62mg/dL [SD±12,67], p=0,0432). CAP tended to be higher in PL patients [301,82dB/m (SD±54,88) vs. 262,93dB/m (SD±57,44); p=0,0685] and LSM was significantly higher (7,32kPa [SD±3,71] vs. 4,94kPa [SD±1,58], p=0,0260).

Conclusions: Patients with PL presented a trend for increased hepatic steatosis and showed higher values of fibrosis in TE. Therefore, we suggest PL patients should undergo TE for screening of NAFLD.


L.C. Viola: None. F.O. Matsuura: None. C.M. Valerio: None. A.F. Godoy-Matos: Speaker's Bureau; Self; Novartis Pharmaceuticals Corporation. Other Relationship; Self; Takeda Development Center Americas, Inc., Novo Nordisk Inc.. M.H. Costa: None. J.M. Araujo-Neto: None. M. Dias: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at